SCHEDULE: Intracoastal Capital Discloses 7.7% Stake in Aethlon Medical

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 7.7% beneficial ownership stake in Aethlon Medical, Inc. as of September 10, 2025.

Summary

• Reporting Persons (Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC) collectively hold a beneficial ownership of 576,603 shares of Aethlon Medical, Inc. Common Stock.
• This represents approximately 7.7% of the company's outstanding Common Stock as of September 10, 2025.
• The ownership includes 21,048 shares directly held by Intracoastal and 555,555 shares issuable upon the exercise of Intracoastal Warrant 2.
• The acquisition of these securities is a result of a Securities Purchase Agreement (SPA) executed on September 4, 2025.
• Warrants issued to Intracoastal contain blocker provisions, preventing beneficial ownership from exceeding 9.99% of the Common Stock.

Sentiment

Score: 6

Explanation: The filing indicates a significant passive investment by an institutional entity, which can be viewed positively as a vote of confidence. However, it is purely an ownership disclosure and does not provide operational or financial performance updates for Aethlon Medical, Inc.

Positives

• A significant institutional investor, Intracoastal Capital, has taken a substantial stake, potentially signaling confidence in Aethlon Medical's prospects.
• The investment is passive, indicating no immediate intent by the reporting persons to disrupt management or strategic direction.

Risks

• Potential for future dilution of existing shareholders if the remaining warrants are fully exercised, although a 9.99% blocker provision limits immediate impact.
• Future changes in the investment strategy or ownership levels by the reporting persons could impact market perception.

Future Outlook

This filing is a disclosure of current ownership and does not provide forward-looking statements or guidance from Aethlon Medical, Inc. The reporting persons have certified that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Management Comments

• The Reporting Persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

Aethlon Medical operates in the medical device and biotechnology sector. A significant passive investment by an institutional entity like Intracoastal Capital could be viewed as a vote of confidence in the company's long-term prospects or its technology, which is particularly relevant in the capital-intensive medical device development industry.

Comparison to Industry Standards

• This filing is a standard disclosure of a significant passive ownership stake, common for institutional investors acquiring more than 5% of a company's shares.
• The inclusion of a 9.99% blocker provision in the warrants is a common practice in such investment agreements to avoid triggering certain regulatory thresholds or shareholder rights plan provisions, aligning with typical industry investment strategies for passive stakes.

Stakeholder Impact

• Shareholders: Increased institutional ownership may lend credibility to the company; however, potential for future dilution exists if warrants are fully exercised without the blocker provision.
• Company: The Securities Purchase Agreement likely provided capital to the company, supporting its operations or development initiatives.

Key Dates

Recommendation

This Schedule 13G filing indicates a significant passive investment by Intracoastal Capital LLC and its principals in Aethlon Medical, Inc., reaching a 7.7% beneficial ownership stake. While the acquisition of a substantial stake by an institutional investor can be interpreted as a vote of confidence, this filing is purely a disclosure of ownership and does not provide new operational or financial performance data for Aethlon Medical. The presence of blocker provisions in the warrants suggests a passive investment strategy, not an intent to influence control. Therefore, without additional information on the company's fundamentals, strategic direction, or recent financial performance, a 'hold' recommendation is appropriate. Investors should consider this ownership alongside other financial and strategic disclosures from Aethlon Medical.

Keywords

Aethlon Medical, Intracoastal Capital, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Biotechnology, Medical Devices